Your browser doesn't support javascript.
loading
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Li, Wei; Xu, Ling; Che, Xiaofang; Li, Haizhou; Zhang, Ye; Song, Na; Wen, Ti; Hou, Kezuo; Yang, Yi; Zhou, Lu; Xin, Xing; Xu, Lu; Zeng, Xue; Shi, Sha; Liu, Yunpeng; Qu, Xiujuan; Teng, Yuee.
  • Li W; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Xu L; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Li H; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Zhang Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Song N; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Wen T; Jinzhou Center Hospital, Jinzhou, 121000, Liaoning, China.
  • Hou K; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Yang Y; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Zhou L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Xin X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Zeng X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Shi S; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Liu Y; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
  • Qu X; Laboratory Animal Center, China Medical University, Shenyang, 110001, Liaoning, China.
  • Teng Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
BMC Cancer ; 18(1): 507, 2018 May 02.
Article en En | MEDLINE | ID: mdl-29720121
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-cbl Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-cbl Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article